Sun Pharma balance sheet and annual report FY2025-26
Sun Pharmaceutical Industries Limited reported consolidated revenue from operations of ₹58,462 crore for FY2025-26 (the year to 31 March 2026) and a net profit of ₹11,479 crore for its shareholders, a net margin of 19.6%. Below are five years of figures from its own annual reports, the ratios worked out from them and links to each report.
Figures from the company's published annual reports. Not investment advice. All figures are consolidated, in ₹ crore, for years ending 31 March. A blank cell means the figure was not in the report we used.
Sun Pharma annual reports, checked 18 November 2026Key figures, FY2021-22 to FY2025-26
| ₹ crore | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 |
|---|---|---|---|---|---|
| Revenue from operations | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 |
| Total income | 39,576 | 44,520 | 49,851 | 54,543 | 60,434 |
| Net profit attributable to owners | 3,273 | 8,474 | 9,576 | 10,929 | 11,479 |
| EPS, basic (₹) | 13.60 | 35.30 | 39.90 | 45.60 | 47.80 |
| Total assets | 69,808 | 80,744 | 85,463 | 92,101 | 1,08,785 |
| Equity attributable to owners | 48,011 | 55,995 | 63,667 | 72,218 | 83,570 |
| Total borrowings | 931 | 6,198 | 2,845 | 1,870 | 4,081 |
| Cash from operations | 8,985 | 4,959 | 12,135 | 14,072 | 12,419 |
| Capital expenditure | 1,495 | 2,086 | 2,202 | 2,129 | 3,609 |
Total borrowings are non-current plus current borrowings, without lease liabilities. Capital expenditure is the line “Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development)” in the cash flow statement.
Revenue from operations Net profit attributable to owners
What changed in FY2025-26
- Revenue from operations rose 11.2% to ₹58,462 crore from ₹52,578 crore.
- Net profit attributable to owners rose 5.0% to ₹11,479 crore from ₹10,929 crore.
- Total borrowings were ₹4,081 crore at 31 March 2026, against ₹1,870 crore a year earlier.
- Cash from operations was ₹12,419 crore and capital expenditure was ₹3,609 crore, so operating cash covered spending on assets 3.4 times.
- Total assets grew 18.1% to ₹1,08,785 crore.
Ratios worked out from these figures
| Ratio | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 |
|---|---|---|---|---|---|
| Net margin | 8.5% | 19.3% | 19.7% | 20.8% | 19.6% |
| Return on equity | 16.3% | 16.0% | 16.1% | 14.7% | |
| Debt to equity | 0.02 | 0.11 | 0.04 | 0.03 | 0.05 |
| Asset growth | 15.7% | 5.8% | 7.8% | 18.1% |
- Net margin = Net profit attributable to owners ÷ revenue from operations × 100
- Return on equity = Net profit attributable to owners ÷ average of opening and closing owners' equity × 100
- Debt to equity = Total borrowings ÷ equity attributable to owners
- Asset growth = Total assets ÷ previous year's total assets − 1, × 100
Return on equity and asset growth need the year before, so the first column is blank. How to read a balance sheet explains each line.
Reading these figures
- Sun Pharma reports in ₹ million. We divide by 10 to show ₹ crore.
Where to read the full report
- Annual Report 2025-26: consolidated financial statements (PDF) figures for FY2024-25 and FY2025-26, checked 18 November 2026
- Annual Report 2023-24: consolidated financial statements (PDF) figures for FY2023-24, checked 18 November 2026
- Annual Report 2022-23: consolidated financial statements (PDF) figures for FY2021-22 and FY2022-23, checked 18 November 2026
Reports are on Sun Pharma's own website, sunpharma.com. We summarise figures only; the reports themselves carry the full statements, notes and the auditor's opinion.
Questions
What is Sun Pharma's net profit for FY2025-26?
Sun Pharma's consolidated net profit attributable to its shareholders was ₹11,479 crore in FY2025-26, up 5.0% from ₹10,929 crore in FY2024-25, as shown in its Annual Report 2025-26: consolidated financial statements.
What is Sun Pharma's revenue for FY2025-26?
Consolidated revenue from operations was ₹58,462 crore in FY2025-26.
How much has Sun Pharma borrowed?
Total borrowings were ₹4,081 crore at 31 March 2026, against equity attributable to owners of ₹83,570 crore.
Where can I download Sun Pharma's annual report?
The Annual Report 2025-26: consolidated financial statements is a PDF on the company's website. The links above go straight to the report for each year we used.
More company financials
- Reliance balance sheet and annual report
- SBI balance sheet and annual report
- ICICI Bank balance sheet and annual report
- Bharti Airtel balance sheet and annual report
- ITC balance sheet and annual report
- HCLTech balance sheet and annual report
- Kotak Mahindra Bank balance sheet and annual report
- Wipro balance sheet and annual report
- Tata Steel balance sheet and annual report
- Asian Paints balance sheet and annual report
- L&T balance sheet and annual report
- Bajaj Finance balance sheet and annual report
- Axis Bank balance sheet and annual report
- Maruti Suzuki balance sheet and annual report
- Tata Motors balance sheet and annual report
- Mahindra & Mahindra balance sheet and annual report
- NTPC balance sheet and annual report
- Titan balance sheet and annual report
- UltraTech Cement balance sheet and annual report
All companies · How to read a balance sheet · Business and accounting calculators · Balance sheet in the glossary